{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:34:29Z","timestamp":1770741269446,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,28]],"date-time":"2017-05-28T00:00:00Z","timestamp":1495929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Telethon","award":["GGP14192"],"award-info":[{"award-number":["GGP14192"]}]},{"name":"EuroBioBank"},{"name":"Telethon Network Genetic Biobanks","award":["GTB12001F"],"award-info":[{"award-number":["GTB12001F"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ymthe.2017.05.019","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T10:15:45Z","timestamp":1497694545000},"page":"2117-2128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology"],"prefix":"10.1016","volume":"25","author":[{"given":"Elisa","family":"Goina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Peruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Bembi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Dardis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Buratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.05.019_bib1","series-title":"The Metabolic and Molecular Basis of Inherited Disease, Vol. III","first-page":"3389","article-title":"Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymthe.2017.05.019_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161A","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1016\/j.ymthe.2017.05.019_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2017.05.019_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2017.05.019_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2017.05.019_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2017.05.019_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajmg.c.31322","article-title":"Toward deconstructing the phenotype of late-onset Pompe disease","volume":"160C","author":"Sch\u00fcller","year":"2012","journal-title":"Am. J. Med. Genet. C. Semin. Med. Genet."},{"key":"10.1016\/j.ymthe.2017.05.019_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2017.05.019_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jpeds.2009.03.015","article-title":"Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease","volume":"155","author":"Chen","year":"2009","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2017.05.019_bib10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.05.019_bib11","first-page":"91","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2017.05.019_bib12","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.05.019_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2017.05.019_bib14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/humu.22108","article-title":"Update of the Pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants","volume":"33","author":"Kroos","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2017.05.019_bib15","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1086\/301788","article-title":"The African origin of the common mutation in African American patients with glycogen-storage disease type II","volume":"62","author":"Becker","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2017.05.019_bib16","first-page":"115","article-title":"Molecular study on the infantile form of Pompe disease in Chinese in Taiwan","volume":"37","author":"Lin","year":"1996","journal-title":"Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi"},{"key":"10.1016\/j.ymthe.2017.05.019_bib17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2017.05.019_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/humu.20374","article-title":"Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II","volume":"27","author":"Montalvo","year":"2006","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2017.05.019_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/01.wnl.0000299892.81127.8e","article-title":"Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency","volume":"70","author":"Nascimbeni","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.05.019_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ymgme.2007.05.011","article-title":"Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G>C mutation","volume":"92","author":"Gort","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2017.05.019_bib21","first-page":"831","article-title":"Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II","volume":"255","author":"Wan","year":"2008","journal-title":"J.\u00a0Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.ymthe.2017.05.019_bib22","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1007\/s10545-008-0820-2","article-title":"Molecular diagnosis of German patients with late-onset glycogen storage disease type II","volume":"31","author":"Joshi","year":"2008","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2017.05.019_bib23","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation","volume":"3","author":"Huie","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2017.05.019_bib24","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2017.05.019_bib25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","article-title":"A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II)","volume":"5","author":"Raben","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2017.05.019_bib26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2017.05.019_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2017.05.019_bib28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4155\/fmc.15.101","article-title":"Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy","volume":"7","author":"Singh","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ymthe.2017.05.019_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/hum.2012.234","article-title":"Clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy","volume":"24","author":"Koo","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.05.019_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/humu.21609","article-title":"SpliceAid 2: a database of human splicing factors expression data and RNA target motifs","volume":"33","author":"Piva","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2017.05.019_bib31","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/nar\/gkp215","article-title":"Human Splicing Finder: an online bioinformatics tool to predict splicing signals","volume":"37","author":"Desmet","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2017.05.019_bib32","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2017.05.019_bib33","first-page":"114","article-title":"New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond","volume":"12","author":"Kishnani","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ymthe.2017.05.019_bib34","first-page":"951","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2017.05.019_bib35","doi-asserted-by":"crossref","first-page":"16054","DOI":"10.1038\/mtm.2016.54","article-title":"TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle","volume":"3","author":"Sato","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.05.019_bib36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2017.05.019_bib37","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/mtna.2016.75","article-title":"From cryptic toward canonical pre-mRNA splicing in Pompe disease: a pipeline for the development of antisense oligonucleotides","volume":"5","author":"Bergsma","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2017.05.019_bib38","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2017.05.019_bib39","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/mtna.2014.57","article-title":"Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease","volume":"3","author":"Clayton","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2017.05.019_bib40","doi-asserted-by":"crossref","first-page":"21510","DOI":"10.1073\/pnas.1211577110","article-title":"Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor","volume":"109","author":"Prudencio","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.05.019_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2003.11.011","article-title":"Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease","volume":"81","author":"Montalvo","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2017.05.019_bib42","doi-asserted-by":"crossref","first-page":"13507","DOI":"10.1016\/S0021-9258(18)92727-4","article-title":"Human lysosomal alpha-glucosidase. Characterization of the catalytic site","volume":"266","author":"Hermans","year":"1991","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617302538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617302538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T20:28:14Z","timestamp":1659126494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617302538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1525001617302538"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s).","name":"copyright","label":"Copyright"}]}}